Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01962961 · ClinicalTrials.gov registry record · Phase 1

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

A Phase 1 study of HIV and Endothelial Dysfunction, sponsored by Indiana University.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT01962961: Completed Phase 1 study of HIV and Endothelial Dysfunction, sponsored by Indiana University.

NCT01962961 is a Phase 1 study of HIV and Endothelial Dysfunction that has completed, run by Indiana University. The registered enrollment target is 24 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01962961, a Phase 1 study of HIV and Endothelial Dysfunction, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine if n-acetylcysteine, given as PharmaNAC, reduces oxidative stress and improves vascular function in HIV-infected older adults already on HIV treatment.

Primary Outcome

Measure of oxidative stress

Conditions Studied

HIV Endothelial Dysfunction Oxidative Stress

Interventions

  • DIETARY_SUPPLEMENT PharmaNAC (N-acetylcysteine)
  • DIETARY_SUPPLEMENT Matching placebo

Study Locations (1)

Indiana

  • Indiana University Health University Hospital, Indiana Clinical Research Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2013-10
Est. Completion 2015-10
Phase Phase 1
Indiana University

890 total trials

What the finished NCT01962961 record still lists

NCT01962961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which PharmaNAC (N-acetylcysteine) is the first listed.

NCT01962961 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT01962961 about?

NCT01962961 is a clinical study titled "N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults". The goal of this study is to determine if n-acetylcysteine, given as PharmaNAC, reduces oxidative stress and improves vascular function in HIV-infected older adults already on HIV treatment.

What is the current status of trial NCT01962961?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2015-10.

What conditions does trial NCT01962961 study?

This clinical trial studies the following conditions: HIV, Endothelial Dysfunction, Oxidative Stress.

What interventions are being tested in trial NCT01962961?

The interventions under investigation include: PharmaNAC (N-acetylcysteine) (DIETARY_SUPPLEMENT), Matching placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01962961?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01962961 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01962961's enrollment target sits among peer trials

24 279th of 303 higher than 23 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01962961, the US trial registry maintained by the National Library of Medicine. NCT01962961 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.